Overview

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Biotech, Inc.

Treatments:

Ustekinumab